|Effect of Paternal Exposure to Pu-239 on the Incidence of Cancer
|Published: Open access to everyone
|Dr. Jeremy Kellington
|BIOLOGICAL SAMPLE AVAILABLE
|Purpose: To determine whether internal contamination with Pu-239 increases the incidence of cancer, in particular leukemias, in the F1 generation of CBA mice.
Status: 1993 - ongoing
Treatment: Intravenous injection with Pu-239 citrate or trisodium citrate of male mice. After 54 days, each male was mated with 2 females for up to 2 weeks and the offspring was followed for a life-time
Dosimetry: Amount injected, determination of Pu-239 in tissues of the injected males including liver, testis and accessory sex organs.
Endpoints: Necropsy observation and histopathology of all macroscopically obvious abnormalities in injected males and F1 offspring.
Animal: Male CBA/Ca mice 10 weeks of age.
Results: The data on Pu-239 content in testes and the corresponding dose have been obtained from the mice used for radiochemistry (see table below). Histopathological analysis showed no abnormalities in the testes of treated animals. No statistical difference between groups was observed with respect to the number of dams becoming pregnant, the number of double-failed matings (both females in the cage), the gestation period or the sex ratio. However, the control group faired worse than the exposed one with respect to pre-weaning mortality, litter size and pup weight. However, since the experiment was started with the controls that improvement of conditions with time could be a confounding factor. The lifespan study of the offspring which is still under way shows some sex differences in mortality, mainly as a result of the high incidence of liver tumours in the male.
|Link to data and details in ERA
|LINK TO FILE